Catalysts / KOD
Upcoming FDA decisions and readouts we track for Kodiak Sciences, each with the filing that announced it.
FreeBioList tracks 3 upcoming catalysts for Kodiak Sciences (KOD, listed on Nasdaq). They cover 2 programmes: Zenkuda (tarcocimab) and KSI-501 (Wet age-related macular degeneration) and KSI-101 (Macular oedema secondary to inflammation (MESI)).
First on the list: the Phase 3 readout for Zenkuda (tarcocimab) and KSI-501 (Wet age-related macular degeneration), guided by the company to Sep 2026. The furthest-out event tracked is Q2 2027. By stage, the upcoming rows are 3 Phase 3 readouts.
All 3 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.
Background reading: How to read a Phase 3 topline readout.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Kodiak Sciences KOD · Nasdaq | Zenkuda (tarcocimab) and KSI-501 | Wet age-related macular degeneration | Sep 2026 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Kodiak Sciences KOD · Nasdaq | KSI-101 | Macular oedema secondary to inflammation (MESI) | Dec 2026 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Kodiak Sciences KOD · Nasdaq | KSI-101 | Macular oedema secondary to inflammation (MESI) | Q2 2027 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList